-

Bayer’s XtendFlex Soybeans Gain Final Key Regulatory Approval

European Commission’s Green Light Enables a Full Launch in 2021

ST. LOUIS--(BUSINESS WIRE)--Bayer announced today that the European Commission has authorized XtendFlex soybean technology for food, feed, import and processing in the European Union. This milestone represents the final key authorization for XtendFlex soybeans. With this approval in hand, Bayer can now look forward to a full launch in the United States and Canada in 2021 and expects to be in a strong position to supply 20 million U.S. soy acres when the selling season arrives.

“XtendFlex soybeans will be Bayer’s second major product launch in soybeans in the last 5 years,” said Lisa Safarian, President of Crop Science North America. “The upcoming launch in 2021 highlights the strength of the Bayer soybean pipeline, as well as the investment that Bayer continues to make in our soybean portfolio and the Roundup Ready Xtend Crop System. XtendFlex soybeans are the latest example of Bayer developing innovative products to help farmers meet challenges on their farm.”

XtendFlex soybeans, Bayer’s newest soybean technology, are built upon the high-yielding Roundup Ready 2 Xtend soybean technology that growers have grown to trust with the additional tolerance to glufosinate herbicides. XtendFlex soybeans provide growers with additional flexibility to manage tough-to-control and resistant weeds.

“We’ve seen great demand for XtendFlex soybeans from our customers,” said Lisa Streck, Bayer soybean launch lead. “Based on that demand, we’ve developed a supply plan to meet the market demand in 2021, across all maturities, Bayer brands and licensees. We expect the launch of XtendFlex to match the launch scale of Roundup Ready 2 Xtend soybeans, which were planted on 20 million acres in their first year of commercial availability. This technology offers outstanding yield potential and weed control flexibility that will benefit soybean farmers across the U.S.”

To learn more about XtendFlex soybeans, please visit RoundupReadyXtend.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Contacts

Bayer - Brian Leake 314.370.3285
brian.leake@Bayer.com

Bayer


Release Versions

Contacts

Bayer - Brian Leake 314.370.3285
brian.leake@Bayer.com

More News From Bayer

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, from August 28-31, 2026. Key Facts Data from two late-breaking presentations will be featured, including a pre-specified subgroup analysis from the Phase III FIND-CKD trial, which evaluated KERENDIA® (finerenone) in patients with CK...

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer, today announced a new formula for One A Day® Women's Multi Gummy, which now delivers 1,000 mcg of Biotin per serving (serving size is two gummies). The new formulation contains more biotin† with 2833% Daily Value (DV) than other leading multivitamin gummies including Olly Women’s Multi, Nature Made Women's Advanced Multivitamin Gummies, and Vitafusion Women's Multi (1000 mcg vs 150 mcg), while continu...

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched health systems, according to new research by Economist Enterprise. The research, supported by Bayer and published in a report titled “Making self-care work: integrating self-care into health systems”, cites existing evidence estimating that self-care practices can deliver approximately US$ 179 bil...
Back to Newsroom